The surface molecule CCR5 is found on tumor cells within liver metastases of colorectal
cancer. Inhibition of this molecule leads to a reduction in growth signals for tumor cells
and subsequent slowed or halted tumor growth. The agent for the inhibition of CCR5 has
already received FDA approval for treatment of HIV and has shown little side effects and
toxicities even on long term treatment. Therefore CCR5-inhibition has the potential of
providing non-toxic tumor growth inhibition.